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ABSTRACT
APO866 is a small molecule drug that specifically inhibits nicotinamide 
phosphoribosyltransferase (NAMPT), a key enzyme involved in nicotinamide adenine 
dinucleotide (NAD) biosynthesis from the natural precursor nicotinamide. Although, the 
antitumor activity of APO866 on various types of cancer models has been reported, 
information regarding mechanisms by which APO866 exerts its cytotoxic effects is not 
well defined. Here we show that APO866 induces a strong, time-dependent increase in 
highly reactive ROS, nitric oxide, cytosolic/mitochondrial superoxide anions and hydrogen 
peroxide. We provide evidence that APO866-mediated ROS production is modulated by 
PARP1 and triggers cell death through mitochondria depolarization and ATP loss. Genetic 
or pharmacologic inhibition of PARP1 prevented hydrogen peroxide accumulation, caspase 
activation, mitochondria depolarization, ATP loss and abrogates APO866-induced cell 
death, suggesting that the integrity of PARP1 status is required for cell death. Conversely, 
PARP1 activating drugs enhanced the anti-leukemia activity of APO866
Collectively, our studies show that APO866 induces ROS/RNS productions, which 
mediate its anti-leukemia effect. These results support testing new combinatorial 
strategies to enhance the antitumor activities of APO866.
INTRODUCTION
The renewed interest in the potential anticancer 
benefit of targeting tumor metabolism has led to an 
intense development of nicotinamide adenine dinucleotide 
(NAD) biosynthesis inhibitors [1–3]. NAD is an essential 
coenzyme in numerous intracellular redox reactions, 
including those that allow ATP (adenosine triphosphate) 
production (i.e. glycolysis and mitochondrial respiration). 
In addition, NAD is the substrate of several important 
NAD-degrading enzymes including poly (ADP-ribose) 
polymerases (PARPs) and sirtuins [4], that, in turn, 
are involved in crucial biological processes, such as 
genomic stability, apoptosis, aging, stress resistance, and 
metabolism [5–7]. In mammals, NAD can be synthesized 
through three main biochemical pathways from five 
distinct precursors: (i) tryptophan through the so-called 
de novo pathway; (ii) nicotinic acid (NA, or its related 
riboside form) through the Preiss-Handler pathway; or 
(iii) nicotinamide (NAM, or its related riboside form) 
through the salvage pathway. NAM/NA are the most 
important available NAD precursor in mammals [8–10]. 
NAMPT is the rate-limiting enzyme that catalyzes the 
phosphoribosylation of NAM to produce nicotinamide 
mononucleotide (NMN) [11, 12]. NMN is subsequently 
converted to NAD by NMN adenylyltransferases. Cancer 
cells have an increased need of NAD compared to normal 
cells, since most cancer cells exhibit a sustained PARP 
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activation due to DNA damage and genomic instability 
[13, 14] and have higher energy demands [15]. Thus, 
tumor cells are more vulnerable to NAD depletion than 
normal cells [1, 16]. This observation has led to the 
development of NAMPT inhibitors, which indeed exhibit 
mechanism-based efficacy against a wide range of human 
solid tumors and blood cancers [2, 16–23]. Exposure of 
cancer cells to NAMPT inhibitors strongly decreases NAD 
cell content, followed by ATP decline that ultimately leads 
to cell death. NAMPT inhibitor-induced cell death occurs 
either in caspase-dependent or –independent manner, 
and is associated with reactive oxygen species (ROS) 
production, mitochondrial dysfunction, and autophagy [1, 
16, 24–28]. However, the role of reactive oxygen/nitrogen 
species (ROS(29)/RNS) productions in NAMPT inhibitor-
mediated cytotoxicity is not defined.
ROS are a group of small, short-lived and highly 
reactive oxygen molecules [30] containing one or more 
unpaired electrons [31, 32]. ROS include molecules such 
as oxygen radicals [superoxide anion (O2
-•), hydroxyl 
radicals (OH•), peroxyl radicals (RO2
•) and alkoxyl radicals 
(RO•)] and non-radicals such as hydrogen peroxide (H2O2) 
hypochlorous acid (HOCl), ozone (O3) and singlet oxygen 
(1O2) [30, 33, 34]. RNS are small molecules that include 
nitric oxide radical (NO•), peroxinitrite (ONOO-), nitrogen 
dioxide radical [14] (NO2
•), other oxides of nitrogen and 
products arising when NO• reacts with O2
-•, RO• and 
RO2
•. Under physiologic conditions and at low/moderate 
concentrations, ROS/RNS play a central role in various 
cellular functions such as gene transcription, cell-cycle 
regulation and cell proliferation [29, 32, 35–37]. However, 
the overproduction of ROS/RNS results in the oxidation/
nitrosylation of cell constituents such as proteins, DNA 
and lipids [30] that leads to cell dysfunction and ultimately 
to cell death [29, 30, 33].
In the present study, we evaluated ROS/RNS 
production in hematopoietic malignant cells treated with 
APO866, a very potent NAMPT inhibitor, and explored 
the role of ROS/RNS generation in APO866-induced cell 
death using pharmacological and genetic tools. We show that 
exposure of leukemia cells to APO866 leads to a tremendous 
increase in various types of ROS/RNS in a dose- and time-
dependent manner. Excessive ROS/RNS release contributes 
to APO866-induced cell death through mitochondria 
depolarization and requires the integrity of PARP1 status. 
Finally, PARP1 activating chemotherapeutic drugs strongly 
potentiate the anti-leukemia activity of APO866.
RESULTS
APO866 dramatically increases ROS/RNS levels 
in hematological malignant cells
In our previous studies, we reported the association 
between APO866 treatment and cO2, mO2, H2O2 
accumulations [26, 38, 39]. Now, we provide a global 
view of the ability of APO866 to generate various type of 
ROS/RNS in hematopoietic malignant cells. We extended 
our investigation to the generation of highly reactive 
ROS (hROS) and NO in APO866-treated hematological 
malignant cells. hROS/NO are known to be detrimental 
to cells, since they chemically modify lipids, proteins, and 
nucleic acids. We took advantage of recently developed 
probes [Aminophenyl fluorescein (APF), hydroxyphenyl 
fluorescein (HPF), in addition to 5,6-Diaminofluorescein 
diacetate (DAF-2/DA)] that detect hROS and NO, 
respectively [40]. Two unrelated leukemia cell lines, 
Jurkat and ML-2 cells, were treated with or without 
APO866 for various time periods and hROS/NO levels 
were detected by flow cytometry and by specific sensitive 
probes. The exposure of hematopoietic malignant cells to 
APO866 was found to lead to a statistically significant 
increase in hROS and NO levels in a time-dependent 
manner until 96 hours (Figure 1A–1C). In parallel assays, 
we also confirmed our previous study, showing that, over 
time, APO866 induced strong increase in cO2, mO2 and 
H2O2 in both hematological malignant cell lines exposed 
to the drug (Figure 1D–1F). Next, we examined whether 
ROS/RNS production is due to NAD depletion. To this 
end, we first measured the intracellular NAD content in 
Jurkat and ML2 cells treated with or without APO866. 
As shown in Figure 1G, NAD depletion precedes ROS/
RNS productions (Figure 1A–1F) in APO866-treated 
hematopoietic malignant. To confirm that oxidative/
nitrosative stress in APO866-treated leukemia cells is a 
consequence of NAD depletion (induced by APO866), 
we evaluated ROS/RNS productions in APO866-treated 
leukemia cells in the presence of exogenous NAD. 
The supplementation with exogenous NAD allowed to 
fully inhibit ROS/RNS productions in APO866-treated 
leukemia cells (Figure 1H and 1I), which strongly suggests 
that NAD depletion is involved in ROS/RNS productions.
Collectively, these data strongly suggest that 
APO866 depletes intracellular NAD content, thereby 
leading to the generation of various types of ROS/RNS.
ROS/RNS generations are required for APO866-
mediated cell death
Next, we evaluated the contribution of ROS/RNS 
productions in APO866-induced cell death in leukemia 
cells. Hematopoietic malignant cells were exposed 
to APO866 in presence or absence of different ROS 
scavengers and cell death was monitored. Catalase, Mito-
TEMPO, dimethyl sulfoxide (DMSO) and N-Nitroarginine 
methyl ester (L-NAME) were used as a scavengers for 
H2O2, mO2, OH radical and NO; respectively. Scavenging 
ROS/RNS generations (Figure 2A–2D) significantly 
attenuates APO866-induced cell death, with catalase 
providing a complete protection from APO866-induced 
cell death. To confirm that cell death protection by 
ROS/RNS scavengers indeed reflects the suppression of 
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oxidative/nitrosative stress, we examined ROS production 
in APO866-treated leukemia cells in presence/or absence 
of catalase. As expected, pretreatment with catalase 
completely abrogated APO866-induced ROS production 
in all tested malignant cells (Figure 3A–3F). Notably, 
NAD depletion was still found to occur in APO866-treated 
leukemia cells despite the presence of exogenous catalase 
(Figure 3G), indicating that the contribution of ROS/
RNS productions to APO866-induced cell death occurs 
downstream of NAD depletion. We previously reported 
the association between APO866-induced cell death and 
ROS productions and hypothesized that the high level 
of APO866-induced ROS levels were responsible for 
mitochondria damage, as highlighted by (i) the loss in 
mitochondria transmembrane potential, (ii) ATP depletion 
and finally (iii) cell death [16, 26]. Here, we examined 
whether scavenging ROS/RNS accumulation in APO866-
treated leukemia cells would prevent mitochondria 
depolarization. Hematopoietic malignant cells were pre-
treated with (or without) catalase before incubation with 
(or without) APO866 and mitochondrial transmembrane 
potential (ΔΨm) was assessed using JC-1 staining and 
flow cytometry. In line with previous studies [16, 26], 
APO866 was found to dissipate ΔΨm in leukemia cells. 
In contrast, prevention of ROS/RNS accumulations 
by catalase supplementation abrogated mitochondria 
depolarization, suggesting that oxidative stress plays a 
key role in APO866-mediated mitochondria depolarization 
(Figure 3H). One of the consequences of mitochondria 
depolarization is ATP loss. Then, we assessed ATP cell 
content in APO866-treated leukemia cells in presence or 
absence of catalase. In agreement with our observation, 
exogenous addition of catalase fully prevents the ATP 
depletion induced by APO866 treatment (Figure 3I). 
These results also indicate that the protective effects of 
ROS/RNS scavengers in APO866-treated leukemia cells 
rely on the abrogation of mitochondrial depolarization and 
thereby preventing the ATP loss.
Figure 1: APO866 depletes NAD content that leads to dramatic increases ROS/RNS levels in hematological malignant 
cells. Time dependent detection of ROS/RNS productions in Jurkat and ML2 cells treated with APO866 (10 nM) with (A–F) or without 
(H–I) exogenous NAD. Highly reactive ROS (A–B), NO (C and H), Cytosolic (D, H and I), mitochondrial superoxide (E, H and I) 
and hydrogen peroxide (F, H and I) were detected by flow cytometry using APF, HPF, DHE, MitoSox, and DCFDA fluorescent probe, 
respectively. (G) Total intracellular NAD content was measured and normalized to relative protein content and expressed compared to 
untreated cells. Data are mean ± SD, n = 3; ***p < 0.001 (vs. untreated cells).
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Figure 2: Scavenging ROS/RNS attenuates APO866-mediated cell death in leukemia cells. Jurkat and ML2 cells were 
incubated with or without (A) catalase (H2O2 scavenger, 1000 U/ml), (B) mitoTempo (mitochondria superoxide scavenger, 5 mM), (C) 
DMSO (hydroxyl radical scavenger, 0.24 mM), or (D) L-NAMAE (NO scavenger, 2 mM) with or without APO866 (10 nM). Cell death 
after 96 hours of drug exposure was assessed by flow cytometry using ANXA5 and 7AAD stainings. The percentage of early apoptotic cells 
(ANN+ 7AAD−) are shown as white columns and that of late apoptotic cells (ANN+ 7AAD+) are shown as solid black columns. Data are 
mean ± SD, n ≥ 3; **P < 0.01; ***P < 0.001.
Figure 3: Catalase supplementation abrogates ROS/RNS production, loss of mitochondria membrane potential and 
ATP, but not NAD depletion in APO866-treated hematological malignant cells. Time dependent detection of ROS/RNS 
productions in Jurkat and ML2 cells treated with APO866 (10 nM) in presence of exogenous addition of catalase. Highly reactive ROS (A–
B), NO (C), Cytosolic (D), mitochondrial superoxide (E) and hydrogen peroxide (F) were detected as described in Figure 1. Detection of 
NAD and ATP cell content (G and I), as well as mitochondrial depolarization (H) in APO866-treated Jurkat and ML2 cells in presence (or 
absence) of catalase (1000 U/ml) were assessed as described in Method section. Total intracellular NAD and ATP contents were measured 
and normalized to relative protein content and are expressed as a ratio compared to that of untreated Jurkat/ML2 cells. 
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Taken together, these results clearly indicate that 
ROS/RNS production is a consequence of NAD depletion 
and that it is involved in the ΔΨm dissipation that, in turn, 
leads to ATP loss contributing to the anti-leukemia activity 
of APO866.
APO866-mediated leukemia cell death requires 
PARP1 integrity
The deleterious effects of hROS/NO are also mediated 
via DNA damage, resulting in PARP1/caspase activations 
and ultimately leading to cell death [34, 35]. To assess 
whether PARP1 is involved in APO866-induced cell 
death, cells from different hematologic malignancies were 
pre-incubated with a potent PARP1 inhibitor (PJ34) prior 
APO866 treatment. PJ34 significantly decreases APO866-
mediated cell death in dose-dependent manner (Figure 
4A), suggesting the implication of PARP1 activation in the 
anti-leukemia effects of the NAMPT inhibitor. To assess 
the generality of our observation and demonstrating that it 
is not restricted to one or two cell lines, we extended our 
investigation to additional leukemia, lymphoma and multiple 
myeloma cell lines and to primary B-CLL and MCL cells 
from patients. PARP1 inhibition confers a significant 
protective effect against APO866-induced cytotoxicity in 
all of the blood cancer cells that were tested (Figure 4B).
In principle, pharmacological inhibition may have 
off target effects. To complement the pharmacological 
PARP1 inhibition and to verify its contribution in the 
anti-leukemia effects of APO866, we generated PARP1 
knockout Jurkat cells (Figure 4C). Sensitivity of Jurkat 
cells to APO866 correlated with PARP1 levels (Figure 
4D). Notably, in the PARP1-KO clone C11-1.1, in which 
PARP1 expression was virtually abrogated, we observed 
a complete resistance to APO866. Thus, the latter clone 
was used for further experiments. We then examined 
whether ROS/RNS accumulation in APO866-treated 
hematopoietic tumor cells depends on PARP1 status. To 
this end, we evaluated the effect of PARP1 deletion on 
ROS production in APO866-treated malignant cells. Wild-
type (WT) or PARP1-KO Jurkat cells were exposed to 
APO866 for various time and intracellular ROS production 
was measured using DHE (for cO2), MitoSOX (mO2), 
carboxy-H2DCFDA (H2O2), and DAF2/DA (NO) and flow 
cytometry. Deletion of PARP1 had no effect on cO2, mO2 
and NO production (Figure 5A–5C), but fully prevented 
the accumulation of H2O2 (Figure 5D). Since H2O2 is 
deleterious to mitochondria, we next examined the effect 
Figure 4: The integrity of PARP1 status is required for the anti-leukemia activity of APO866. Cell lines and primary cells 
from different hematological malignancies were treated without or with 10 nM of APO866 in the presence or absence of a pharmacological 
inhibition (A–B) or genetic deletion (D) of PARP1 and cell death assessed as described in Figure 2. PARP1 was knocked out (KO) in wild-
type (WT) Jurkat cells using CRISPR/Cas9 technology. Loss of expression was confirmed by Western blotting (C). 
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of PARP1 KO on mitochondria depolarization. Deletion of 
PARP1 prevented ΔΨm loss in response to APO866 (Figure 
5E). Mitochondria depolarization is expected to release 
cytochrome c, which in turn leads to caspase activation 
and, consequently, to DNA degradation and ATP depletion. 
PARP1 deletion fully prevented caspase activation and 
ATP loss in APO866-treated leukemia cells (Figure 
5F–5G). To get further insights into the contribution of 
PARP1 in the metabolism of oxidative stress, we carried 
out a pilot study by comparing the expression levels of 84 
genes that regulate oxidative stress (including antioxidant 
genes) in WT versus PARP1-KO Jurkat cells in presence 
or absence of APO866. In agreement with the above data, 
genetic deletion of PARP1 showed that of the 84 genes 
analyzed, changes in mRNA (fold change > 1.5) were 
detected in 21 genes: 5 upregulated and 16 downregulated 
(Table 1). Most of downregulated genes are involved in 
the production of oxidative stress. In addition, treatment 
of PARP1-KO Jurkat cells with APO866 resulted in 
upregulation of 6 powerful antioxidant genes, including 
CAT and genes known to increase tumor cell survival such 
SIRT2 and UCP2 (Table 2). Taken together, these results 
suggest that oxidative stress (including H2O2 production) 
is modulated by PARP1, and that H2O2 plays a key role in 
the mitochondrial depolarization, caspase activation, ATP 
loss, and cell death.
PARP1 activating agents sensitize leukemia cells 
to APO866 treatment
Understanding the molecular mechanisms involved 
in APO866-induced cell death enabled us to establish a 
rationale for combinatorial strategy with APO866 that 
could increase its cytotoxic activity in hematopoietic 
cancer cells. Specifically, based on the above-mentioned 
data, we hypothesized that chemotherapeutic agents 
that activate PARP1 (such as alkylating agents) or that 
boost ROS production could sensitize leukemia cells to 
APO866. To test our hypothesis, we treated hematopoietic 
malignant cells with (or without) APO866 in presence (or 
absence) of exogenously added H2O2 and assessed cell 
death as described above. Exogenous supplementation 
of H2O2 in APO866-treated leukemia cells, significantly 
increased the anti-leukemia activity of APO866 (Figure 
6A) and shortened the time required to achieve cytotoxic 
activity from 96 hours to 24 hours (Figure 6B), indicating 
that ROS-producing chemotherapeutic drugs could 
sensitize leukemia cells to APO866. Next, we evaluated 
the ability of etoposide (a PARP1 activating drug through 
topoisomerase II inhibition) to sensitize leukemia cells to 
APO866. Hematopoietic malignant cells were exposed 
to etoposide alone or to the combination of etoposide 
and APO866 for 96 hours and subsequently measured 
Figure 5: Deletion of PARP1 fully inhibits H2O2 production, mitochondrial depolarization, caspase activation, and loss 
of ATP cell content in APO866-treated Jurkat cells. Detection of cytosolic (A), mitochondrial (B) superoxide anions, NO (C), 
H2O2 generation (D) and MMP (E), and ATP cell content (G) in APO866-treated WT or KO Jurkat cells were monitored as described in 
Figure 1. (F) Caspase 3 activation was assessed in WT (or PARP1KO) Jurkat cells treated with 10 nM APO866 for 96 h using a fluorescent 
specific probe for activated forms of CAS P3 and flow cytometry.
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cell death as described above. Etoposide plus APO866 
treatment significantly increased cell death as compared to 
each drug alone in all cells tested (Figure 6C). We further 
evaluated the effects of the combined action of etoposide 
(or H2O2) and of APO866, by calculating a CI for each 
combination. The CI for etoposide/H2O2 and APO866 was 
< 1 for all of the tested leukemia cell lines, indicating a 
synergistic effects of this combination in these malignant 
cells (Tables 3 and 4). Collectively, these data indicate 
that PARP1 activating drugs could potentiate the anti-
leukemia activity of APO866. Finally, to assess whether 
sensitization of leukemia cells to APO866 by etoposide 
involves PARP1 activity, PARP1-KO malignant cells were 
exposed to etoposide alone or etoposide plus APO866 
for 96 hours before assessing their viability. Deletion of 
PARP1status abrogated the synergistic effect of combined 
APO866 and etoposide (Figure 6D).
DISCUSSION
Here we show that the NAMPT inhibitor APO866 
is a very potent inducer of different types of ROS/RNS, 
including cO2/mO2, H2O2, NO and hROS and that these 
strongly contribute to its anti-leukemia activity. ROS/RNS 
accumulation under the modulation of PARP1 triggers 
mitochondrial depolarization and ATP depletion, and 
finally APO866-induced cell death. In line with this model, 
supplementation with exogenous ROS scavenging agents, 
such catalase or inhibition of PARP1, were found to protect 
from APO866-induced cytotoxicity. To our knowledge, 
this is the first study to report such diversity of ROS/RNS 
productions in APO866-treated leukemia cells. Our data 
indicate that in response to APO866 treatment, mO2, cO2 
and NO production is independent of PARP1 status, whereas 
H2O2 generation depends on the PARP1 integrity status. Of 
















PXDN NM_012293 Peroxidasin 2.03 4.06 1.67 –1.16
PNKP NM_007254 Polynucleotide kinase 3’-phosphatase 1.87 3.66 1.64 –1.27
STK25 NM_006374 Serine/threonine kinase 25 1.85 3.61 1.67 1.39
SRXN1 NM_080725 Sulfiredoxin 1 1.59 4.35 2.29 1.31
ALOX12 NM_000697 Arachidonate 12-lipoxygenase 1.57 3.63 1.94 –1.43
MSRA NM_012331 Methionine sulfoxidereductase A –3.86 –2.83 1.14 –1.11
MBL2 NM_000242 Mannose-binding lectin 2 –2.77 –2.11 1.1 –1.21
MB NM_005368 Myoglobin –2.77 –2.11 1.1 –1.21
GPX6 NM_182701 Glutathione peroxidase 6 –2.77 –2.11 1.1 –1.21
ALB NM_000477 Albumin –2.77 –2.11 1.1 –1.21
GPX5 NM_001509 Glutathione peroxidase 5 –2.77 –2.11 1.1 –1.21
SFTPD NM_003019 Surfactant protein D –2.77 –2.11 1.1 –1.21
PTGS2 NM_000963 Prostaglandin-endoperoxidesynthase 2 –2.77 –2.11 1.1 –1.21
NOX5 NM_024505 NADPH oxidase, EF-hand calcium binding domain 5 –2.77 –2.11 1.1 –1.21
NOX4 NM_016931 NADPH oxidase 4 –2.77 –2.11 1.1 –1.21
APOE NM_000041 Apolipoprotein E –2.1 –1.49 1.18 –1.3
LPO NM_006151 Lactoperoxidase –2.01 –2.11 –1.25 –1.21
MT3 NM_005954 Metallothionein 3 –1.67 –1.99 –1.42 –1.09
GPX3 NM_002084 Glutathione peroxidase 3 –1.62 1.09 1.49 –1.38
PRDX3 NM_006793 Peroxiredoxin 3 –1.58 1.01 1.34 1.21
AOX1 NM_001159 Aldehyde oxidase 1 –1.53 –1.04 1.22 –1.06
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interest, PARP1 proficiency in cancer cells is required for 
APO866 to be cytotoxic in these cells. The present study also 
highlights the role of PARP1 in oxidative stress production, 
the cumulative anti-leukemia potentials of APO866 and 
chemotherapeutic drugs that active PARP1, such as etoposide.
ROS accumulation in APO866-treated 
hematological malignant cells is in agreement with 
previous studies reporting ROS production in malignant 
cells treated with NAMPT inhibitors [41, 42]. The 
enhanced ROS production in APO866-treated malignant 
cells could be explained, at least in part, by the fact that, by 
depleting intracellular NAD content, APO866 affects the 
NAD(P)/NAD(P)H ratio as reported in our previous study 
[43], thus altering the cellular redox status. The impaired 
ability of leukemia cells treated with APO866 to perform 
ROS scavenging would then result in enhanced oxidative/
nitrosative stress highlighted by the strongly increased 
ROS/RNS levels. In this regard, the NADP(H) cell content 
has been shown to contribute to the variability in metabolic 
response to NAD depletion [42]. We clearly demonstrated 
the involvement of ROS production in APO866-mediated 
cytotoxicity. Specifically, our data strongly suggest that 
APO866 induces NAD depletion that leads to oxidative 
stress mode shown by the production of various types of 
ROS/RNS, particularly H2O2, which triggers cell death 
via the mitochondrial apoptotic pathway. Our result 
suggest also that PARP1 status plays an important role 
in oxidative stress and cell death. To explain this finding, 
we provide strong evidence that PARP1 regulates the 
expression level of oxidative stress genes. In line with this 
observation, we showed that genetic inhibition of PARP1 
resulted in downregulation of several genes involved in 
oxidative stress metabolism. Treatment of PARP1-KO 
leukemic cells with APO866 led also to an upregulation 
of antioxidant genes including (catalase and other genes 
DHCR24, GSR, UCP2, SIRT2…) that are known to play 
a crucial role in drug resistance in different types of cancer 
cell, which could provide a plausible explanation on how 
PARP1-KO leukemic cells displayed less sensitivities to 
APO866.
We cannot rule out that the accumulation of ROS 
(Figure 1A–1F) due to NAD depletion (Figure 1G) 
could lead to DNA damage [44] thus activating PARP1 
[43]. The activation of PARP1 could contribute to the 
exacerbation of NADP(H) cell content depletion [43], 
which in turn will lead to the reduction in the antioxidant 
cell capacity through depletion of potent antioxidant 
enzymes (Tables 1 and 2) such, superoxide dismutase, 
and heme oxygenase 1 [45] and ultimately result in the 
observed increase in H2O2 production (Figure 1F). To 
demonstrate that NAD depletion is the primary cause 
of ROS accumulation, exogenous addition of NAD full 
inhibited ROS/RNS production (Figure 1H and 1I). 
Alternativelly and not mutually exclusive, we showed 
that ROS/RNS production provokes the disruption of 
mitochondria ΔΨm (Figure 3H). Mitochondria play a 


















SIRT2 NM_012237 Sirtuin 2 –1.07 3.76 3.37 1.44
GSR NM_000637 Glutathione reductase 1.13 4.29 3.19 1.01
UCP2 NM_003355 Uncoupling protein 2 –1.82 1.62 2.48 –1.68
DHCR24 NM_014762 24-dehydrocholesterol reductase 1.22 3.27 2.24 1.32
TXNRD1 NM_003330 Thioredoxin reductase 1 –1.06 2.2 1.99 –1.1
SOD2 NM_000636 Superoxide dismutase 2, mitochondrial 1.06 2.2 1.73 1.3
CAT NM_001752 Catalase –1.19 1.7 1.7 1.35




Rac exchange factor 1
1.06 1.91 1.5 1.01
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crucial role in energy metabolism and, perhaps even more 
importantly, in regulation of cell death [37]. Excessive 
ROS production can lead to mitochondria dysfunction, 
culminating in ATP depletion (Figure 3I) and, ultimately, 
in cell demise through the release of intra-mitochondrial 
enzymes involved in cell death such apoptotic protease 
activating factor 1 (apaf-1), cytochrome c, apoptosis-
inducing factor (AIF), endoG. In line with the hypothesis, 
we showed that APO866 induces high level of ROS/RNS 
productions, and that H2O2 acts downstream of PARP1 
in mediating APO866’s antilekeumia effects, suggesting 
that H2O2 accumulation is modulated by PARP1 status. 
The contribution of PARP1 in the depletion of antioxidant 
leukemia cell capacity (catalase; heme oxygenase-1) is 
suggested by the fact that genetic deletion of PARP1 
indeed fully blunted H2O2 generation in APO866-treated 
cancer cells, via regulation of several genes involved 
in oxidative stress, including many antioxidant genes. 
In addition, we previously reported that APO866 is 
effective at depletion catalase [26, 43]. Blocking either 
ROS accumulation by exogenous addition of catalase or 
knocking out PARP1, were able to abrogate mitochondria 
depolarization, ATP loss and to fully inhibit cell death 
in response to APO866 treatment. Our results suggest 
that APO866 triggers parthanatos in leukemia cells. 
Parthanatos is a highly programed form of cell death, 
which occurs through the overactivation of PARP-1 
[46]. Under normal conditions, PARP1 is involved in 
DNA repair. To maintain genomic homeostasis, PARP1 
detects single strand DNA breaks, it uses NAD to catalyze 
Figure 6: Exogenous supplementation of H2O2 or etoposide potentiates the anti-leukemia activity of APO866. APO866-
treated WT or PARP1 KO cells from different human leukemia exposed to H2O2 (A) or not (B), or etoposide (C and D) alone or in 
combination for 24 hours (H2O2) or 96 hours (Etoposide). Cell death was assessed as described in Figure 2. Data are mean ± SD, n = 3; 
**p < 0.001 (drug combination vs. each drug alone). 
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the polyADP-ribosylation of PARP1 itself as well as of 
numerous other target proteins [5, 47]. This leads to 
the recruitment to the DNA damage sites of proteins 
that are critical for DNA repair [47]. However, PARP1 
hyperactivation leads to NAD and ATP depletion and to 
the translocation of AIF from the mitochondria to the 
nucleus [48, 49]. In response to APO866, NAD depletion 
occurs upstream of PARP1 involvement. Based on our 
results, we cannot rule out the possibility that NAMPT 
inhibition may trigger other types of cell death in other 
cancer cells. In agreement with this observation, it was 
reported that NAD depletion could induce oncosis in non 
haematological cancer cells [50]. Further experiments 
are warranted to elucidate the key molecular events that 
control the cell death mechanisms triggered by NAMPT 
inhibitor-mediated NAD depletion and how does PARP1 
to regulate oxidative stress genes. It is noteworthy to 
mention that although, we showed that PARP1 inhibition 
confers a protection from APO866-induced cell toxicity 
in a broad range of leukemia cells, it was reported 
elsewhere that NAMPT inhibition significantly enhanced 
the sensitivity of triple-negative (ER-, PR-, HER2-
negative) breast cancer cells to olaparib (PARP1 inhibitor) 
treatment [51]. The increased sensitivity of TN breast 
cancer cells to olaparid in presence of NAMPT inhibitor 
could be due most probably to the defect in homologous 
recombination genes (such as loss-of-function BRCA1 or 
BRCA2 mutations).
We show that the chemotherapeutic drug, etoposide, 
that activates PARP1, or exogenous supplementation 
with H2O2 could be a successful strategy to sensitize 
leukemia cells to APO866. Particularly, such an 
approach is anticipated to be a valuable strategy as long 
as APO866-induced cell death is dependent on PARP1 
activation (parthanatos). This observation is line with 
previous studies showing that the killing effects of 
NAMPT inhibitors could be increased by co-treatment 
with: (i) DNA-damaging drugs [25, 52] such etoposide, 
as cisplatin, 1-methyl-3-nitro-1-nitrosoguanidinium [53], 
fluorouracil [54] and (ii) ionizing radiations.
In conclusion, we demonstrated that APO866 
induces the production of high levels of various types 
of ROS/RNS that depend on PARP1 integrity and 
playing a crucial role in its anti-leukemia activity. ROS/
RNS accumulation triggers APO866-induced cell death 
through mitochondria depolarization, caspase activation 
and finally, to ATP depletion. We show that etoposide 
sensitizes leukemia cells to APO866 via PARP1 status. 
These findings suggest potential approaches to enhance 
the antitumor activity of APO866, by modulating the 
parthanatos pathway. Defining the molecular mechanisms 
underlying APO866-induced cytotoxicity is going to 
improve our understanding of the effects of NAD depletion 
in leukemia cells and it will aid in the development of 
novel anticancer therapy strategies.
MATERIALS AND METHODS
Cell lines and culture conditions
Seven hematological cancer cell lines were 
purchased from DSMZ (German Collection of 
Microorganisms and Cell Cultures) or ATCC and include 
Jurkat and Molt-4 (T-acute lymphoblastic leukemia); 
ML-2 and THP-1 (acute myeloid leukemia); RPMI8226 
and U266 (multiple myeloma) and Raji (Burkitt 
lymphoma).
Primary cells from four patients were also analyzed. 
The ethics committee at the University of Lausanne 
approved study protocols. Primary cells were collected 
from peripheral blood (purity > 90%) from patients with 
mantle cell lymphoma (MCL; n = 1); and B-chronic 
lymphocytic leukemia (CLL; n = 3).
All cells were cultured in RPMI (Invitrogen AG, 
61870-01) supplemented with 10% heat inactivated fetal 
calf serum (Amimed, 2-01F30-I) and 1% penicillin/
streptomycin at 37°C (Amimed, 4-01F00-H) in a 
humidified atmosphere of 95% air and 5% CO2.
Flow cytometer analyses
Various cellular effects induced by clinical grade 
APO866, (kindly provided by TopoTarget, Switzerland), 
on hematopoietic malignant cells were evaluated using a 
Beckman Coulter Cytomics Gallios flow cytometer and 
included following functional cell parameters: cell death, 
ROS/RNS productions, and mitochondrial membrane 
potential.
Table 4: Synergistic effect of Etoposide and APO866 on different leukemic cells
Cell line Jurkat ML2
CI 0.3 0.1
Abbreviations: CI, cooperative index.
Table 3: Synergistic effect of H2O2 and APO866 on different leukemic cells
Cell line Jurkat ML2 THP1
CI 0.4 0.5 0.3
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Cell death analysis
APO866-induced cell death was determined using 
ANNEXIN-V (ANN; eBioscience, BMS306FI/300) and 
7-aminoactinomycin D (7AAD; Immunotech, A07704) 
stainings as described by the manufacturer and analyzed 
using a flow cytometry. Dead cells were identified as ANN+ 
and/or 7AAD +. Specific cell death induced by drug was 
calculated using the following formula: percent cell death 
induced by drug = [(S - C) / (100 - C)] x 100; where S = 
treated sample cell death and C = untreated sample cell death.
Assessment of mitochondrial membrane 
potential
MMP was determined using flow cytometry after 
cell staining with 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbe
nzimididazolylcarbocyanine iodide (JC-1, Calbiochem, 
420200-5). JC-1 is a cell permeant, fluorescent dye 
that readily accumulates in active mitochondria due to 
their relative negative charge. JC-1 accumulates in the 
mitochondria, showing green fluorescence at a low MMP 
and forming red fluorescent J-aggregates at higher MMP. 
A drop in MMP is indicated by a decrease in the ratio 
of the red signal to the green signal. Briefly, cells were 
cultured in the presence or absence of APO866 for 24 to 
96 h. Cells were centrifuged, resuspended in phosphate-
buffered saline (PBS) containing 5 μM JC-1, and were 
then incubated at 37°C for 15 min in the dark. The cells 
were washed twice with prewarmed PBS, and immediately 
analyzed using flow cytometry.
Detection of cellular and mitochondrial reactive 
oxygen/nitrogen species (ROS/RNS)
Various type of ROS/RNS were determined in 
APO866- and control- treated hematopoietic malignant 
cells by flow cytometry using live-cell permeant specific 
fluorogenic probes. DHE as probe for detection of cytosolic 
superoxide anion (cO2
•-), MitoSox as probe for detection 
of mitochondrial superoxide anion (mO2
•-), carboxy-
H2DCFDA as probe for detection of H2O2. APF and HPF 
as probes for detection of highly reactive oxygen/nitrogen 
species (hROS) that include singlet, hydroxyl radical, 
peroxynitrite anion, or hypochlorite anion. DAF-2/DA was 
used as probe for detection of intracellular NO. DHE is 
oxidized to red fluorescent ethidium by cytosolic superoxide 
and MitoSox is selectively targeted to mitochondria, 
where it is oxidized by superoxide and exhibits red 
fluorescence. 6-carboxy-2′,7′-dichlorodihydrofluorescein 
diacetate (carboxy-H2DCFDA) is cleaved by esterase 
to yield DCFH, a polar non-fluorescent product, but in 
presence of hydrogen peroxide, the latter is oxidized to 
green fluorescent product, dichlorofluorescent (DCF). APF 
and HPF reagents are nonfluorescent and produce bright 
green fluorescence upon reaction with hydroxyl radical or 
peroxynitrite anion, APF also reacts with the hypochlorite 
anion. DAF-2/Da is a membrane permeable, fluorescent 
that is hydrolyzed to DAF-2 by intracellular esterases 
and can be used as real-time indicator for NO level. For 
cell staining, cells were centrifuged and the pellets were 
resuspended in PBS with a final concentration of 5 μM for 
each probe. The mixture was incubated in the dark at 37°C 
for 15 min. Then, the cell suspension was analyzed using a 
flow cytometry within 20 min.
NAD and ATP quantification
Cells (0.5 × 106) in log growth phase were seeded in 
6-well plates in presence or absence of drug as mentioned 
above. Cells were then centrifuged at 900 g (2000 rpm) 
for 5 min. Supernatant was discarded and cells were 
resuspended in 250 µL lysis buffer and kept at –80°C for at 
least 4 h before analysis. Total NAD content was measured 
in cell lysates using a biochemical assay described 
elsewhere [10]. Cell lysate (20 µL) was plated in a 96-
well flat bottom plate. A standard curve was generated 
using a 1:3 serial dilution in lysis buffer of a β-NAD 
stock solution. Cycling buffer (160 µL) was added into 
each well and the plate was incubated for 5 min at 37°C. 
Ethanol (20 µL), prewarmed at 37°C, was added into each 
well and the plate was incubated for an additional 5 min at 
37°C. Absorbance at 570 nm was read after 5, 10, 15, 20, 
and 30 min at 37°C on a spectrophotometer. The amount 
of NAD in each sample was normalized to the protein 
content for each test sample.
Total ATP cell content was quantified using the ATP 
determination Kit (Life Technologies, A22066) according 
to manufacturer’s instructions.
Plasmids
The lentiviral vector lentiCRISPR [55] was obtained 
from Addgene (#868, Addgene, ref. no. 52961). The 
pMD2.G plasmid (#554, Addgene, ref. no. 12259) encodes 
the envelope of lentivirus. The psPAX2 plasmid (#842, 
Addgene, ref. no. 12260) encodes the packaging system. 
LeGOiG2-Bcl-XL (#863) was constructed by subcloning 
the 771 bp EcoRI fragment from hBcl-XL.dn3 (#274) into 
LeGOiG2 (#807; Addgene: plasmid 27341).
Lentivirus production
Recombinant lentiviruses (LentiCRISPRs) 
were produced as described [56] with the following 
modification: pMD.G and pCMVDR8.91 were replaced 
by pMD2.G and psPAX2 respectively.
Genome editing by CRISPR method
Single guide RNAS targeting the early 
exon (exon number 2) of PARP1 were chosen in 
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the sgRNA library [57]. LentiCRISPR plasmid 
specific for PARP1 gene was created according to 
the provided instructions. Oligonucleotides were 
designed as follow: Forward 5′-CACCGTTCTAGTC 
GCCCATGTTTGA-3′; Reverse 3′-AACTCAAACATGG 
GCGACTAGAAC-5′. Oligonucleotides were synthetized, 
then phosphorylated and annealed to form oligo 
complex. LentiCRISPR vector was BsmBI digested and 
dephosphorylated. Linearized vector was purified and gel 
extracted and ligated to oligo complex. The lentiCRISPR 
vector containing the sgRNA was then used for virus 
production. Cells were infected and selected with the 
appropriate dose of puromycin (1 µg/ml). Clone isolation 
was performed by limiting dilution in 96 well-plate.
TA cloning
TA cloning kit (Life technologies, K202020) was 
used according to manufacturer’s instructions to sequence 
DNA fragment containing the region where Cas9 was 
guided by a sgRNA.
Immunoblotting
Protein samples were harvested in lysis buffer 
containing 20 mM HEPES, pH 7.4, 10 mM NaCl, 3 mM 
MgCl2, 2.5 mM EGTA, 0.1 mM dithiothreitol, 50 mM 
NaF, 1 mM Na3VO4 or for LC3 expression analysis in a 
Tris–HCl buffer, pH 7.4, containing 150 mM NaCl, 5 mM 
EDTA, 1% triton X-100, 2 mM sodium orthovanadate, 
0.5 mM phenylmethylsulphonyl fluoride, 0.05% aprotinin 
(w/v), and 1 mM dithiotreitol. A protease inhibitor 
cocktail (Roche, 11873580001) was added. Lysates were 
sonicated and protein concentration was determined using 
a Bradford assay. Proteins (25–40 μg) were separated by 
SDS-PAGE on an 8, 10 or 14% polyacrylamide gel, and 
analyzed by immunoblotting. The mouse anti-PARP1 and 
the rabbit anti-actin antibodies were from Cell Signaling 
(9546 and 4970 respectively). After incubation with 
primary antibody, the following secondary antibodies were 
applied: polyclonal goat anti-mouse or goat anti-rabbit 
IgG conjugated with IRDye 680 (LI-COR, B70920-02) 
or IRDye 800 (LI-COR, 926-32210). Protein bands were 
visualized using the Odyssey Infrared Imaging System 
(LI-COR). Odyssey v1.2 software (LI-COR) was used 
for densitometric analysis. Data were expressed as a 
percentage of values obtained for control non-treated cells.
Gene expressions involved in oxidative stress by 
real-time PCR array analysis PCR analysis
The Human Oxidative Stress Plus RT2 Profiler PCR 
Array (PAHS-065Z) was used to analyze mRNA levels of 
84 key genes related to oxidative stress (antioxidants, ROS 
metabolism and pathway activity signature genes) in a 96-
well format, according to the manufacturer’s instructions 
(Qiagen). WT or PARP1 KO Jurkat cells were treated with 
or without APO866 at 10 nM for 40 hours. Reactions were 
run on a Real-Time PCR system, Bio-Rad CFX96, using 
RT2 SYBR Green PCR master mix (Qiagen, Switerland). 
The thermocycler parameters were 95°C for 10 min, 
followed by 40 cycles of 95°C for 15 s and 60°C for 1 
min. Relative changes in gene expression analysis were 
performed according to QIAGEN Web software using 
the ΔΔCT method with normalization of the raw data to 
5 housekeeping genes. The expression data are presented 
as real change multiples. Genes with altered expression 
profile compared to control with fold change value ≥ ±1.5 
and P < 0.05 were presented.
Evaluation of cooperative index
To assess a possible synergism between APO866 
and Eto (or H2O2), a cooperative index (CI), was 
calculated based on the Chou-Talalay method [58–60]. We 
used the following formula: CI = sum of specific apoptosis 
of single agent treatment/specific apoptosis of combined 
treatment. The percentage of specific apoptosis was 
calculated using the following formula: specific apoptosis 
= (drug-induced apoptosis – spontaneous apoptosis) / (100 
– spontaneous apoptosis) x 100. When CI < 1, CI = 1, and 
CI > 1, the effects were defined as synergistic, additive, 
and infra-additive, respectively.
Statistical analysis
All assays were performed in triplicate and expressed 
as the mean and standard deviation (SD). All pair-wise 
comparisons were analyzed by Tukey-Kramer multiple 
comparisons test or by one-way ANOVA followed by 
Student’s t-test (2-tailed, 2-sample and unequal variance). 
GraphPad Prism version 6.00 (GraphPad Software, San 
Diego, CA, USA) was used for statistical analysis. P values 
< .05 were considered statistically significant.
Abbreviations
7AAD: 7-aminoactinomycin D; ANN: 
Annexin-V; APF: aminophenyl fluorescein; ATP: 
adenosine triphosphate; B-CLL: B-chronic lymphocytic 
leukemia; carboxy-H2DCFDA: 6-carboxy-2′,7′-
dichlorodihydrofluorescein diacetate; CI: cooperative 
index; DAF-2/DA: 5,6-Diaminofluorescein diacetate; 
ETO: etoposide; HPF: hydroxyphenyl fluorescein; JC-1: 
5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimididazolylcarb
ocyanine iodide; KO: knock-out; L-NAME: N-Nitroarginine 
methyl ester; MCL: mantle cell lymphoma; NA: nicotinic 
acid; NAD: nicotinamide adenine dinucleotide; NAD(P)
H: dihydronicotinamide-adenine dinucleotide phosphate; 
NMN: nicotinamide mononucleotide; Nam: nicotinamide; 
NAMPT: nicotinamide phosphoribosyltransferase; PARP1: 
poly (ADP-ribose) polymerase-1; RNS: reactive nitrogen 
species; ROS: reactive oxygen species.
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